Abstract
A series of 301 cases of male breast carcinoma has been analysed; of these, 292 have been treated at The Christie Hospital, Manchester and followed-up for a maximum of 15 years. The mean age was 63 years. The corrected survival was 52%, 38% and 36% at 5, 10 and 15 years respectively. For clinical Stage I, the 15 year survival was 61%. Since 1976, adjuvant Tamoxifen for one year has been administered to patients with operable Stage II (path) and Stage III disease following surgery and radiotherapy. Twenty-three patients so treated have a corrected survival of 55% at 5 years compared to 28% previously. Of 22 tumours assayed for oestrogen and progesterone receptors, 86% showed a positive result. For recurrent/metastatic disease, the drug Tamoxifen is recommended as the treatment of choice.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barnes D. M., Ribeiro G. G., Skinner L. G. Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment. Eur J Cancer. 1977 Oct;13(10):1133–1143. doi: 10.1016/0014-2964(77)90012-3. [DOI] [PubMed] [Google Scholar]
- Calabresi E., De Giuli G., Becciolini A., Giannotti P., Lombardi G., Serio M. Plasma estrogens and androgens in male breast cancer. J Steroid Biochem. 1976 Aug;7:605–609. doi: 10.1016/0022-4731(76)90084-4. [DOI] [PubMed] [Google Scholar]
- Dao T. L., Morreal C., Nemoto T. Urinary estrogen excretion in men with breast cancer. N Engl J Med. 1973 Jul 19;289(3):138–140. doi: 10.1056/NEJM197307192890307. [DOI] [PubMed] [Google Scholar]
- Langlands A. O., Maclean N., Kerr G. R. Carcinoma of the male breast: report of a series of 88 cases. Clin Radiol. 1976 Jan;27(1):21–25. doi: 10.1016/s0009-9260(76)80008-6. [DOI] [PubMed] [Google Scholar]
- Moss N. H. Cancer of the male breast. Ann N Y Acad Sci. 1964 Apr 2;114(2):937–950. [PubMed] [Google Scholar]
- Nirmul D., Pegoraro R. J., Jialal I., Naidoo C., Joubert S. M. The sex hormone profile of male patients with breast cancer. Br J Cancer. 1983 Sep;48(3):423–427. doi: 10.1038/bjc.1983.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Norris H. J., Taylor H. B. Carcinoma of the male breast. Cancer. 1969 Jun;23(6):1428–1435. doi: 10.1002/1097-0142(196906)23:6<1428::aid-cncr2820230626>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- Ribeiro G. G. Carcinoma of the male breast: A review of 200 cases. Br J Surg. 1977 Jun;64(6):381–383. doi: 10.1002/bjs.1800640602. [DOI] [PubMed] [Google Scholar]
- Ribeiro G. G. Tamoxifen in the treatment of male breast carcinoma. Clin Radiol. 1983 Nov;34(6):625–628. doi: 10.1016/s0009-9260(83)80408-5. [DOI] [PubMed] [Google Scholar]
- Ribeiro G. G. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer. 1976 Apr;33(4):465–467. doi: 10.1038/bjc.1976.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scheike O., Svenstrup B., Frandsen V. A. Male breast cancer. II. Metabolism of oestradiol-17 beta in men with breast cancer. J Steroid Biochem. 1973 Sep;4(5):489–501. doi: 10.1016/0022-4731(73)90064-2. [DOI] [PubMed] [Google Scholar]